Publications by authors named "Mark D Pegram"

Claim this Profile
S
Spontaneous upregulation of stemness and 3D spheroid formation of single cancer cells induced by scaffold-free polypeptide polyelectrolyte multilayer coating.
Jia-Yang Chen, Chia-Chun Liu, Lucas Wang, Hang-Shiang Jiang, Pei-Syuan Lu, Mark D Pegram

Biomaterials· March 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
Xiaosong Chen, Jiahui Huang, Haoting Shi, Juanying Zhu, Weizhu Wu, Mark Daniel Pegram

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
Tara B Sanft, Jenna Wong, Brandon O'Neal, Natalia Siuliukina, Rachel C Jankowitz, Mark D Pegram

J Natl Compr Canc Netw· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.
Volkmar Müller, Rupert Bartsch, Nancy U Lin, Filippo Montemurro, Mark D Pegram

Cancer Treat Rev· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D Pegram

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, Timothy J Pluard, Julie R Nangia, Mark D Pegram

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Metabolic Abnormalities and Breast Cancer: Challenges From Bench to Bedside.
Zheng Wang, Pu Li, Mark Daniel Pegram, Xiaosong Chen

Front Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Antonino Musolino, William J Gradishar, Hope S Rugo, Jeffrey L Nordstrom, Edwin P Rock, Mark D Pegram

J Immunother Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell immunoblotting resolves estrogen receptor-α isoforms in breast cancer.
John J Kim, Wenchuan Liang, Chi-Chih Kang, Mark D Pegram, Amy E Herr

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data.
Louis E Fernandes, Caroline G Epstein, Alexandria M Bobe, Joshua S K Bell, Martin C Stumpe, Mark D Pegram

Clin Breast Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.
Mark D Pegram, Erika P Hamilton, Antoinette R Tan, Anna Maria Storniolo, Kemal Balic

Mol Cancer Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Rosalynd Upton, Allison Banuelos, Dongdong Feng, Tanuka Biswas, Kevin Kao, Mark D Pegram

Proc Natl Acad Sci U S A· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortés, Giuseppe Curigliano, Mark D Pegram

JAMA Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice.
Liyang Cui, Arvin M Gouw, Edward L LaGory, Shenghao Guo, Nabeel Attarwala, Mark D Pegram

Nat Biotechnol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Robyn M Barfield, Yun Cheol Kim, Stepan Chuprakov, Fangjiu Zhang, Maxine Bauzon, Mark D Pegram

Mol Cancer Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular Vesicle-Mediated Transcribed mRNA Delivery for Treatment of HER2 Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity.
Alexis V Forterre, Jing-Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D Pegram

Mol Cancer Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Mark D Pegram, David Miles, C Kimberly Tsui, Yu Zong

Clin Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induced pluripotent stem cells as a novel cancer vaccine.
Lin Wang, Mark D Pegram, Joseph C Wu

Expert Opin Biol Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Branimir I Sikic, Nehal Lakhani, Amita Patnaik, Sumit A Shah, Sreenivasa R Chandana, Mark D Pegram

J Clin Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Manjiri M Bakre, Charusheila Ramkumar, Arun Kumar Attuluri, Chetana Basavaraj, Chandra Prakash, Mark D Pegram

Cancer Med· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Mark D Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, Sachin Hingmire, Hirotaka Iwase

Br J Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.
Jing-Hung Wang, Alexis V Forterre, Jinjing Zhao, Daniel O Frimannsson, Alain Delcayre, Mark D Pegram

Mol Cancer Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.
Mark D Pegram, Yu Zong, Clinton Yam, Matthew P Goetz, Stacy L Moulder

Am Soc Clin Oncol Educ Book· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.
Chi-Chih Kang, Toby M Ward, Jessica Bockhorn, Courtney Schiffman, Haiyan Huang, Mark D Pegram

NPJ Precis Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Marzia A Locatelli, Philippe Aftimos, E Claire Dees, Patricia M LoRusso, Mark D Pegram

Oncotarget· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis